Home >   Products   >  Advanced Search

Rolipram
(CAS RN:61413-54-5 Product Number:R0110)

Structure

Rolipram
Synonym 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone

General Information

Product Number R0110

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +32 (0)3 735 07 00 E-mail: Sales-EU@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(HPLC)
Storage Temperature -20°C
M.F. / M.W. C16H21NO3=275.35
CAS RN 61413-54-5
Related CAS RN
MDL Number MFCD00270906
Packaging and Container
  • Product Details
  • Safety & Regulations

Specification

Purity(HPLC) min. 98.0 area%
Melting point 130.0 to 134.0 deg-C

References

Reaxys-RN 1588548
PubChem SID 253659657
Merck Index(14) 8251
RTECS# UY5749237
EC Number 262-771-1

Transport Information

HS Number 2933790090

Application

Rolipram: A Selective PDE4 Inhibitor

Rolipram is a selective inhibitor of phosphodiesterases 4 (PDE4s) originally developed as an antidepressant agent in 1990s, but fell out of favor because of its undesirable gastrointestinal side effects. Nowadays, rolipram continues to be used in research as a PDE4 inhibitor. PDE4s are responsible for hydrolysis of the cyclic nucleotides cAMP [A2381] and cGMP to 5’-AMP [A0158] and 5’-GMP [G0338], particularly in nerve and immune cells. The inhibition of PDE4s by rolipram induces the elevation of intracellular cAMP concentration. Consequences rolipram-induced elevation of cAMP suppress expression of proinflammatory cytokines and other mediators of inflammation. Rolipram has been reported as a drug for the treatment of autoimmune diseases, Alzheimer's disease, cognitive enhancement, and respiratory diseases like asthma and COPD. Rolipram is a racemic compound, and (R)-rolipram [R0182] is more potent than (S)-rolipram [R0183] as a PDE4 inhibitor. (The product is for research purpose only.)

References

PubMed Literature

Page Top